Paradigm Biopharmaceuticals Limited
PBIGF
$0.2083
$0.00633.12%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -1.93M | -1.98M | -3.19M | -3.19M | -16.30M |
| Total Depreciation and Amortization | 23.30K | 23.90K | 24.20K | 24.10K | 23.90K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 17.70K | 18.20K | 111.50K | 111.20K | 296.00K |
| Change in Net Operating Assets | -789.00K | -811.20K | -1.86M | -1.85M | -646.90K |
| Cash from Operations | -2.68M | -2.75M | -4.92M | -4.91M | -16.63M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.10K | 15.50K | -15.20K | -15.20K | 15.10K |
| Cash from Investing | 15.10K | 15.50K | -15.20K | -15.20K | 15.10K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -29.00K | -29.00K | -25.50K | -25.50K | -25.70K |
| Issuance of Common Stock | 8.00M | 8.00M | 0.00 | 0.00 | 15.06M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -412.70K | -412.70K | -37.30K | -37.30K | -881.50K |
| Cash from Financing | 4.93M | 5.06M | -41.40K | -41.30K | 9.22M |
| Foreign Exchange rate Adjustments | 4.30K | 4.50K | -209.80K | -209.30K | -35.20K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.27M | 2.33M | -5.18M | -5.17M | -7.42M |